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TrastuzumabAbstract Background: In the phase III, open-label, randomised HannaH study, fixed-dose
neoadjuvanteadjuvant subcutaneous trastuzumab for human epidermal growth factor recep-
tor 2 (HER2)-positive early breast cancer was non-inferior to standard weight-based intrave-
nous infusion in terms of serum trough concentration and pathological complete response
(pCR). Evidence suggests that pCR, particularly total pCR (tpCR), is likely to predict clinical
benefit. We report associations between tpCR and event-free survival (EFS) from HannaH
(the largest population from a single study of patients presenting with newly diagnosed
HER2-positive breast cancer treated with neoadjuvanteadjuvant trastuzumab to date) plus
long-term efficacy and safety.
Methods: Eligible patients received four cycles of neoadjuvant docetaxel followed by four cy-
cles of fluorouracil/epirubicin/cyclophosphamide administered concurrently with 3-weekly
subcutaneous (600 mg fixed dose) or intravenous trastuzumab (8 mg/kg loading, 6 mg/kg
maintenance doses). Post-surgery, patients received adjuvant trastuzumab as randomised to
complete 1 year of standard treatment. In exploratory analyses, we used Cox regression to
assess associations between tpCR and EFS. EFS rates per subgroup were estimated using
the KaplaneMeier method.
Findings: Three-year EFS rates were 76% for subcutaneous and 73% for intravenous trastuzu-
mab (unstratified hazard ratio [HR] 0.95, 95% confidence interval [CI] 0.69e1.30; intention-to-
treat population). Three-year overall survival rates were 92% for subcutaneous and 90% for
intravenous trastuzumab (unstratified HR 0.76, 95% CI 0.44e1.32). tpCR was associated with
a reduced risk of an EFS event: subcutaneous arm HR 0.38 (95% CI 0.22e0.65); intravenous
arm HR 0.32 (95% CI 0.18e0.60). Results were similar for subgroups, including oestrogen re-
ceptor status. The few additional adverse events occurring during treatment-free follow-up
were balanced between arms.
Interpretation: Long-term efficacy supports the established non-inferiority of subcutaneous
trastuzumab, and its safety profile remains consistent with the known intravenous profile.
In each of HannaH’s treatment arms, tpCR was associated with improved EFS, adding to ev-
idence that tpCR is associated with clinical benefit in HER2-positive early breast cancer.
ª 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
One year of subcutaneous trastuzumab (Herceptin SC;
F. Hoffmann-La Roche Ltd, Basel, Switzerland) is
approved in over 60 countries worldwide as neoadjuvant
and adjuvant therapy for human epidermal growth
factor receptor 2 (HER2)-positive early breast cancer,
and its advantages over intravenous trastuzumab
(Herceptin, F. Hoffmann-La Roche Ltd) include time
savings and convenience for patients and health care
professionals [1e3]. Patients reported preference for
subcutaneous trastuzumab because it saves time and, in
contrast with clinically reported adverse events, causes
less pain/discomfort/side-effects [3e5]. Approval of
subcutaneous trastuzumab was based on results of the
HannaH phase III study; with almost 600 patients,
HannaH is the largest single study in patients with
HER2-positive early breast cancer homogeneously
treated with neoadjuvanteadjuvant trastuzumab. Han-
naH confirmed non-inferiority of subcutaneous versus
intravenous trastuzumab in terms of the co-primary
end-points of serum trough concentration (Ctrough) and
pathological complete response (pCR) [6]. Additional
analyses at 20 months’ median overall follow-upconfirmed the 12-month analysis finding that subcu-
taneous trastuzumab was generally well tolerated, with
adverse event and event-free survival (EFS) rates com-
parable to those seen with intravenous trastuzumab [7].
We now report per-protocol long-term efficacy (EFS
and overall survival [OS]) and safety from the HannaH
study with a median overall follow-up of approximately
40 months, after the last patient had completed 1 year of
neoadjuvanteadjuvant treatment and at least 2 years of
additional treatment-free follow-up (clinical cut-off).
HannaH’s study design also allowed exploratory ana-
lyses of the association between pCR and EFS. Prior
studies have indicated that pCR, and in particular total
pCR (tpCR; absence of invasive neoplastic cells in the
breast and ipsilateral lymph nodes, regardless of ductal
carcinoma in situ), is likely to predict clinical benefit in
patients with HER2-positive early breast cancer [8e14].
Moreover, the US Food and Drug Administration
(FDA) and the European Medicines Agency (EMA)
define pCR as the absence of cancer in the breast and
ipsilateral (regional) lymph nodes [15,16]. This definition
is equivalent to the definition of tpCR in HannaH.
Thus, tpCR is used for the main association analyses
here.
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2.1. Study design, patients, randomisation, and masking
HannaH is an open-label, multicentre, international,
randomised phase III study, the design of which has beenA
B
Fig. 1. Trial profile. ‘*’, Two patients were prematurely withdrawn due
but nevertheless underwent surgery and are included in the efficacy pe
treatment at the end of the neoadjuvant phase, did not receive adjuvan
phase. ‘z’, One patient did not undergo primary surgery after completio
due to insufficient therapeutic response. ‘k’, In the intravenous trastu
trastuzumab arm, one patient withdrew consent. These patients did no
who consented to 2 years of follow-up under Protocol Amendment B o
time of analysis. ‘yy’, Includes three patients with termination page midescribed [6]. HannaH was performed in accordance with
Good Clinical Practice guidelines and the Declaration of
Helsinki, and all patients provided written informed con-
sent.Approval for the studyprotocol andall accompanying
material provided to the patients were obtained from in-
dependent ethics committees at participating institutions.to disease progression after completion of eight cycles of treatment
r-protocol population. ‘y’, Includes one patient who discontinued
t treatment, and underwent surgery in the treatment-free follow-up
n of the neoadjuvant phase. ‘x’, Includes one patient who withdrew
zumab arm, two patients withdrew consent. In the subcutaneous
t enter treatment-free follow-up for event-free survival. ‘{’, Patients
nly. ‘**’, Includes seven patients with termination page missing at
ssing at time of analysis. IVZ intravenous; SCZ subcutaneous.
Table 1
Baseline patient demographic and tumour characteristics for the
intention-to-treat population.
Subcutaneous
trastuzumab
(nZ 294)
Intravenous
trastuzumab
(nZ 297)
Age (years) 50.0 (25e81) 50.0 (24e77)
Body weight (kg) 68.0 (39.0e136.0) 66.2 (42.0e137.1)
Region
Eastern Europe 114 (38.8%) 122 (41.1%)
Asia-Pacific 63 (21.4%) 59 (19.9%)
Western Europe and
Canada
51 (17.3%) 56 (18.9%)
South America 50 (17.0%) 45 (15.2%)
South Africa 16 (5.4%) 15 (5.1%)
Ethnic origin
White 197 (67.0%) 207 (69.7%)
Asian 64 (21.8%) 61 (20.5%)
Other 33 (11.2%) 29 (9.8%)
Left ventricular
ejection fractiona
66.0% (53e87) 65.0% (55e82)
Breast cancer typeb
Operablec 151 (51.4%) 163 (54.9%)
Locally advancedd 123 (41.8%) 115 (38.7%)
Inflammatory 20 (6.8%) 19 (6.4%)
Breast cancer subtypee
Ductal 272 (92.8%) 273 (91.9%)
Lobular 12 (4.1%) 17 (5.7%)
Other 9 (3.1%) 7 (2.4%)
Oestrogen receptor
statusb
Negative 140 (47.6%) 148 (49.8%)
Positive 154 (52.4%) 148 (49.8%)
Unknown 0 1 (0.3%)
Histological grade
Well differentiated 13 (4.4%) 8 (2.7%)
Moderately
differentiated
152 (51.7%) 151 (50.8%)
Poorly differentiated 128 (43.5%) 137 (46.1%)
Anaplastic 0 1 (0.3%)
Unknown 1 (0.3%) 0
Clinical nodal statuse
cN0 71 (24.2%) 62 (20.9%)
cN1 129 (44.0%) 151 (50.8%)
cN2 60 (20.5%) 50 (16.8%)
cN3 33 (11.3%) 34 (11.4%)
Clinical tumour
statuse
cT1b 2 (0.7%) 2 (0.7%)
cT1c 17 (5.8%) 21 (7.1%)
cT2 129 (44.0%) 130 (43.8%)
cT3 52 (17.7%) 49 (16.5%)
cT4abc 73 (24.9%) 76 (25.6%)
cT4d 20 (6.8%) 19 (6.4%)
Data are median (range) or number (%).
a nZ 293 for the subcutaneous trastuzumab arm and nZ 296 for
the intravenous trastuzumab arm.
b Stratification factors.
c Clinical stage cT1becT3, cN0ecN1.
d Clinical stage cT1becT4c, cN2ecN3.
e nZ 293 for the subcutaneous trastuzumab arm and nZ 297 for
the intravenous trastuzumab arm.
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Patients were randomised to receive eight cycles of
neoadjuvant chemotherapy, administered concurrentlywith trastuzumab, every 3 weeks either intravenously
(8 mg/kg loading dose, 6 mg/kg maintenance dose) or
subcutaneously (fixed dose of 600 mg). Chemotherapy
comprised four cycles of docetaxel (75 mg/m2) followed
by four cycles of fluorouracil (500 mg/m2), epirubicin
(75 mg/m2), and cyclophosphamide (500 mg/m2). Post-
surgery, patients received ten cycles of trastuzumab to
complete 1 year of neoadjuvanteadjuvant therapy [6].
For the present analysis, patients were followed for ef-
ficacy and safety for 2 years after the last dose of study
medication. Reporting time windows for adverse events
are listed in Supplementary Table S1.
2.3. Outcomes
The secondary end-points of EFS, OS, and safety were
assessed at this clinical cut-off. EFS was defined as time
from randomisation to the date of disease recurrence or
progression (local, regional, distant, or contralateral), or
death from any cause. OS was defined as time from
randomisation to death and a final analysis will be
carried out once 5 years of survival data have been
collected. Adverse events and serious adverse events
were recorded and graded according to standard criteria
[17e19]. Safety for this analysis is focused on the
treatment-free follow-up phase.
2.4. Statistical analyses
Target sample sizes andpower calculations for theprimary
analysis have been reported [6]. Long-term efficacy ana-
lyses are focused on the intention-to-treat (ITT) popula-
tion, which includes all patients who had at least one
efficacy assessment after first study drug administration.
Analyses were also conducted on the efficacy per-protocol
(EPP) population (all randomised patients without major
protocol violations: a full descriptionof criteria is shown in
the Supplementary Materials) [7]. Results for the EPP
population are shown in the Supplementary Materials, as
results are similar to the ITT population.
Exploratory EFS sub-analyses included EFS by age
(cut-off: 65 years), oestrogen receptor status, Ctrough
quartiles at pre-dose cycle 8, body weight quartiles,
tpCR, and pCR. The association between tpCR and
EFS was also assessed according to oestrogen receptor
status, a stratification factor in HannaH. For explor-
atory tpCR/pCReEFS associations in the ITT popula-
tion, patients withdrawn prior to surgery were counted
as non-responders. EFS rates and unstratified hazard
ratios (HRs)/confidence intervals (CIs) were estimated
using the KaplaneMeier method and Cox regression,
respectively. tpCR/pCReEFS associations were ana-
lysed using multivariable Cox modelling. To investigate
if the association between tpCR/pCR and EFS was
different in the two arms, a Cox regression model on
EFS with a treatmentetpCR/pCR interaction term was
used (interaction p-value <0.1 was used as indicator of
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Fig. 2. Event-free survival for the intention-to-treat population. CIZ confidence interval; HRZ hazard ratio.
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Fig. 3. Event-free survival for subgroups related to efficacy of the fixed subcutaneous dose in the intention-to-treat population.
CIZ confidence interval; CtroughZ serum trough concentration.
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performed with SAS, v9.2 (SAS Institute Inc., Cary,
NC, USA). The safety population included all patients
who received at least one dose of study drug, and
adverse events are described overall and during the
treatment-free follow-up period.
HannaH is registered with ClinicalTrials.gov, number
NCT00950300.3. Results
In total, 596 eligible patients were enrolled between 19th
October 2009 and 1st December 2010: 297 patients were
randomised to receive subcutaneous trastuzumab and
299 were randomised to receive intravenous trastuzu-
mab [6]. ITT populations were 294 and 297 patients,
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safety populations, 297 and 298 patients [6]. Patient
dispositions for the neoadjuvanteadjuvant and
treatment-free follow-up phases are shown in Fig. 1.
Demographic characteristics of the ITT population
(Table 1) were balanced and consistent with those of the
EPP population [6]. At clinical cut-off (17th January
2014), median follow-up was 40.3 months with subcu-
taneous trastuzumab (range 0.3e50.7) and 40.6 months
with intravenous trastuzumab (range 1.0e51.0).
Median trastuzumab dose intensity was 196.4 mg/
week (range 163.2208.0) in the subcutaneous arm and
135.6 mg/week (range 86.9234.6) in the intravenous
arm; median relative dose intensities were >98% in both
arms. Median relative dose intensities for all chemo-
therapy agents were 99% in both arms (Supplementary
Table S2).
Of the ITT population, 154 of 294 patients in the
subcutaneous arm and 148 of 297 patients in the intra-
venous arm had oestrogen receptor-positive tumours. Of
these patients, 133 of 154 (86.4%) and 120 of 148
(81.1%) subsequently received at least one endocrine
therapy, respectively; the most common being tamoxifen
(99 of 154 patients [64.3%] in the subcutaneous arm and
79 of 148 [53.4%] in the intravenous arm) and aromatase
inhibitors (37 of 154 patients [24.0%] in the subcutane-
ous arm and 42 of 148 patients [28.4%] in the intrave-
nous arm). A complete list is shown in Supplementary
Table S3.Secondary efficacy end-point
Event-free survival (ITT population)
Event-free survival (EPP population)
Overall survival (ITT population)
Overall survival (EPP population)
0·5
Favours subcutaneo
Fig. 4. Event-free and overall survival in the intention-to-treat popu
protocol; ITTZ intention-to-treat; HR = hazard ratio.
Table 2
Event-free survival according to treatment and total pathological complete
Subcutaneous trastuzuma
tpCR (nZ 108) N
KaplaneMeier 3-year EFS rate (95% CI) 88% (82e94%) 69
Cox regression HR (95% CI) 0.38 (0.22e
CIZ confidence interval; EFSZ event-free survival; HRZ hazard ratio; t
a Includes patients withdrawn before surgery.At clinical cut-off, EFS rates 3 years after random-
isation were 76% in the subcutaneous arm and 73% in
the intravenous arm, and the resulting HR was 0.95
(95% CI 0.69e1.30) (Figs 2e4). HRs were similar in
both arms across Ctrough pre-dose cycle 8 and body
weight quartiles (Fig. 3). Results were not affected by
age, the HR for subcutaneous versus intravenous tras-
tuzumab being 0.94 (95% CI 0.67e1.31) in patients aged
<65 years and 1.03 (95% CI 0.39e2.72) in patients aged
65 years. EFS results were also similar between the
arms by oestrogen receptor status (HR 0.86 [95% CI
0.54e1.38] for oestrogen receptor-positive disease and
1.04 [95% CI 0.68e1.59] for oestrogen receptor-negative
disease/unknown disease status). In addition, 3-year
EFS rates were higher in oestrogen receptor-positive
disease versus oestrogen receptor-negative disease/un-
known oestrogen receptor status for both subcutaneous
and intravenous trastuzumab: 79% and 73% in the
subcutaneous arm and 76% and 71% in the intravenous
arm.
Patients who achieved tpCR had a >60% reduction
in the risk of an EFS event compared with those who
did not: HR 0.38 (95% CI 0.22e0.65) in the subcu-
taneous arm and 0.32 (95% CI 0.18e0.60) in the intra-
venous arm (Table 2). This finding was also reflected in
the EFS KaplaneMeier curves, graphically presented
for each arm separately in Fig. 5A and B, translating
into 3-year EFS rates which were approximately 20
percentage points higher for patients who achieved1 1·5 2·0
us trastuzumab Favours intravenous trastuzumab 
HR
lation and efficacy per-protocol populations. EPPZ efficacy per
response status of the intention-to-treat population.
b (nZ 294) Intravenous trastuzumab (nZ 297)
o tpCR (nZ 186)a tpCR (nZ 94) No tpCR (nZ 203)a
% (62e76%) 87% (80e94%) 67% (61e74%)
0.65) 0.32 (0.18e0.60)
pCRZ total pathological complete response.
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Fig. 5. Event-free survival according to tpCR status of the intention-to-treat population. CIZ confidence interval; HRZ hazard ratio;
tpCRZ total pathological complete response.
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Fig. 5C shows a similar relationship of tpCR with EFS
for both arms (treatmentetpCR interaction test:
pZ 0.67).
The benefit to 3-year EFS rates when achieving tpCR
was similar between oestrogen receptor-positive disease
and oestrogen receptor-negative disease/unknown oes-
trogen receptor status when study arms were pooled: HR
0.21 (95% CI 0.09e0.53) and 0.35 (95% CI 0.22e0.57),
corresponding to 22 and 23 percentage point-higher 3-
year EFS rates, respectively, when compared with those
who did not achieve tpCR (Table 3). KaplaneMeier
plots of the oestrogen receptor-positive disease and
oestrogen receptor-negative/unknown oestrogen recep-
tor status groups according to tpCR status and study
arm are shown in Fig. 6 and reveal consistent results.
At the data cut-off date, the 3-year OS rate was 92%
for subcutaneous trastuzumab and 90% for intravenous
trastuzumab (HR 0.76, 95% CI 0.44e1.32) (Fig. 4).
Efficacy results in the EPP population were consistent
with those in the ITT population and pCR results were
consistent with tpCR results in both the ITT and EPP
populations (Fig. 4, Supplementary Tables S4eS9,
Supplementary Figs. S1eS5).
Overall safety findings are summarised in Table 4
and are consistent with previous reports [6,7]. More
patients reported serious adverse events in the subcu-
taneous arm, but no pattern in the types of events was
identified that would account for different rates be-
tween the arms. During treatment-free follow-up,
adverse event rates were balanced, with few serious
events observed in the 2 years after completion of
treatment (Table 5). During this period, one adverse
event case (endometrial cancer) led to death with sub-
cutaneous trastuzumab and two adverse event cases
(emphysema and myeloid leukaemia) led to death with
intravenous trastuzumab. Analysis of data from all
phases of the study showed that the overall cardiac
safety profiles of subcutaneous and intravenous tras-
tuzumab remained comparable, with the percentage of
patients with 1 cardiac event being similar in both
arms (14.1% [42 of 297 patients] with subcutaneous
trastuzumab and 13.4% [40 of 298 patients] with
intravenous trastuzumab). The most common cardiacTable 3
Event-free survival according to oestrogen receptor and total pathological
study arms).
Oestrogen receptor-positive (nZ
tpCR (nZ 71) No tpC
KaplaneMeier 3-year EFS rate 94% 72%
Cox regression HR (95% CI) 0.21 (0.09e0.53)
CIZ confidence interval; EFSZ event-free survival; HRZ hazard ratio; t
a Includes patients withdrawn before surgery.adverse events were left ventricular dysfunction (3.4%
of patients [ten of 297] with subcutaneous trastuzumab
[eight resolved] and 3.7% [11 of 298] with intravenous
trastuzumab [nine resolved]) and tachycardia (2.0% of
patients [six of 297] with subcutaneous trastuzumab
[five resolved] and 3.0% [nine of 298] with intravenous
trastuzumab [all resolved]). Two patients (0.7%) expe-
rienced congestive heart failure with subcutaneous
trastuzumab; one case reported as resolved and one
reported as resolved with sequelae. Few patients expe-
rienced cardiac adverse events during the treatment-free
follow-up phase and proportions of those who did were
comparable between treatment arms (1.7% with sub-
cutaneous trastuzumab and 1.3% with intravenous
trastuzumab). In the lower body weight quartiles, car-
diac adverse events were well balanced between treat-
ment arms (Table 6).4. Discussion
The HannaH phase III study provides data from the
largest homogeneous population of patients with
HER2-positive early breast cancer. In HannaH, the
secondary long-term efficacy end-points, EFS and OS,
at a median follow-up of more than 40 months, support
the established non-inferiority of subcutaneous
trastuzumab relative to intravenous trastuzumab as
per the co-primary end-points, pCR and Ctrough.
HannaH’s results were robust and consistent across
analysis populations, and in agreement with the neo-
adjuvanteadjuvant NeOAdjuvant Herceptin (NOAH)
study of intravenous trastuzumab, where 3-year EFS
was 71% for trastuzumab-treated patients [20]. In
general, results were consistent across subgroups
(including demographic and disease characteristics). In
particular, EFS results for both arms were similar in
patients in the higher body weight patient quartiles, as
compared with the overall population, which is
important as higher body weight patients may have
reduced trastuzumab exposure from the 600 mg every 3
weeks subcutaneous fixed dose compared with weight-
based intravenous dosing.complete response status of the intention-to-treat population (pooled
302) Oestrogen receptor-negative or
status unknown (nZ 289)
R (nZ 231)a tpCR (nZ 131) No tpCR (nZ 158)a
84% 61%
0.35 (0.22e0.57)
pCRZ total pathological complete response.
Number at risk
ER-positive:
subcutaneous trastuzumab/tpCR 43 42 42 42 42 42 33 12 1 0 0
ER-positive:
subcutaneous trastuzumab/no tpCR 111 102 96 93 83 77 61 19 1 0 0
Es
tim
at
ed
 p
ro
ba
bi
lit
y
1.0A
B
C
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Follow-up (months)
0 6 12 18 24 30 36 42 48 54 60
ER-positive: subcutaneous trastuzumab/tpCR
ER-positive: subcutaneous trastuzumab/no tpCR
Number at risk
ER-positive:
intravenous trastuzumab/tpCR 28 28 28 28 26 25 24 10 2 0 0
ER-positive:
intravenous trastuzumab/no tpCR 120 108 102 98 90 84 71 27 2 0 0
Es
tim
at
ed
 p
ro
ba
bi
lit
y
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Follow-up (months)
0 6 12 18 24 30 36 42 48 54 60
ER-positive: intravenous trastuzumab/tpCR
ER-positive: intravenous trastuzumab/no tpCR
Number at risk
ER-positive:
subcutaneous trastuzumab/tpCR 43 42 42 42 42 42 33 12 1 0 0
ER-positive:
subcutaneous trastuzumab/no tpCR 111 102 96 93 83 77 61 19 1 0 0
ER-positive:
intravenous trastuzumab/tpCR 28 28 28 28 26 25 24 10 2 0 0
ER-positive:
intravenous trastuzumab/no tpCR 120 108 102 98 90 84 71 27 2 0 0
Es
tim
at
ed
 p
ro
ba
bi
lit
y
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Follow-up (months)
0 6 12 18 24 30 36 42 48 54 60
ER-positive: intravenous trastuzumab/tpCR
ER-positive: intravenous trastuzumab/no tpCR
ER-positive: subcutaneous trastuzumab/tpCR
ER-positive: subcutaneous trastuzumab/no tpCR
Fig. 6. Event-free survival according to oestrogen receptor and tpCR status of the intention-to-treat population. (A)e(C) Represent
oestrogen receptor-positive disease and (D)e(F) represent oestrogen receptor-negative disease/unknown disease status. tpCRZ total
pathological complete response; ER Z oestrogen receptor.
Number at risk
ER-negative/unknown:
subcutaneous trastuzumab/tpCR 65 65 63 61 56 52 39 15 1 0 0
ER-negative/unknown:
subcutaneous trastuzumab/no tpCR 75 65 63 56 50 44 35 11 0 0 0
Es
tim
at
ed
 p
ro
ba
bi
lit
y
1.0D
E
F
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Follow-up (months)
0 6 12 18 24 30 36 42 48 54 60
ER-negative/unknown: subcutaneous trastuzumab/tpCR
ER-negative/unknown: subcutaneous trastuzumab/no tpCR
Number at risk
ER-negative/unknown:
intravenous trastuzumab/tpCR 66 66 65 60 55 53 47 18 0 0 0
ER-negative/unknown:
intravenous trastuzumab/no tpCR 83 77 69 59 54 51 39 12 0 0 0
Es
tim
at
ed
 p
ro
ba
bi
lit
y
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Follow-up (months)
0 6 12 18 24 30 36 42 48 54 60
ER-negative/unknown: intravenous trastuzumab/tpCR
ER-negative/unknown: intravenous trastuzumab/no tpCR
Number at risk
ER-negative/unknown:
subcutaneous trastuzumab/tpCR 65 65 63 61 56 52 39 15 1 0 0
ER-negative/unknown:
subcutaneous trastuzumab/no tpCR 75 65 63 56 50 44 35 11 0 0 0
ER-negative/unknown:
intravenous trastuzumab/tpCR 66 66 65 60 55 53 47 18 0 0 0
ER-negative/unknown:
intravenous trastuzumab/no tpCR 83 77 69 59 54 51 39 12 0 0 0
Es
tim
at
ed
 p
ro
ba
bi
lit
y
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Follow-up (months)
0 6 12 18 24 30 36 42 48 54 60
ER-negative/unknown: intravenous trastuzumab/tpCR
ER-negative/unknown: intravenous trastuzumab/no tpCR
ER-negative/unknown: subcutaneous trastuzumab/tpCR
ER-negative/unknown: subcutaneous trastuzumab/no tpCR
Fig. 6. (Continued)
Table 4
Safety overview (safety population).
Overall Treatment-free follow-up
Subcutaneous trastuzumab
(nZ 297)
Intravenous trastuzumab
(nZ 298)
Subcutaneous trastuzumab
(nZ 297)
Intravenous trastuzumab
(nZ 298)
Patients with 1 adverse
event (any grade)
290 (97.6%) 282 (94.6%) 7 (2.4%) 7 (2.3%)
Patients with 1 grade
3e5 adverse event
158 (53.2%) 158 (53.0%) 2 (0.7%) 3 (1.0%)
Patients with 1 serious
adverse event
65 (21.9%) 43 (14.4%) 2 (0.7%) 3 (1.0%)
Patients with 1 related
serious adverse event
31 (10.4%) 24 (8.1%) 1 (0.3%) 0
Patients with adverse
events leading to death
4 (1.3%) 3 (1.0%) 1 (0.3%) 2 (0.7%)
Data are number (%).
Table 5
Overview of serious adverse events during the treatment-free follow-up
period (safety population).
Subcutaneous
trastuzumab
(nZ 297)
Intravenous
trastuzumab
(nZ 298)
Total 2 (0.7%) 3 (1.0%)
Endometrial cancer 1 (0.3%)a 0
Myeloid leukaemia 0 1 (0.3%)a
Congestive heart
failure
1 (0.3%) 0
Goitre 0 1 (0.3%)
Emphysema 0 1 (0.3%)a
Data are number (%).
a Led to death.
Table 6
Cardiac adverse events by body weight quartiles (safety population).
Subcutaneous
trastuzumab
(nZ 297)
Intravenous
trastuzumab
(nZ 298)
<59 kg 6/71 (8.5%) 9/77 (11.7%)
59 kg, <68 kg 8/70 (11.4%) 9/84 (10.7%)
68 kg, <79 kg 14/71 (19.7%) 6/70 (8.6%)
79 kg 14/85 (16.5%) 16/67 (23.9%)
Data are n/N (%).
C. Jackisch et al. / European Journal of Cancer 62 (2016) 62e7572No new safety signals were observed at this data
cut-off and only a limited number of additional
adverse events were observed during the treatment-
free follow-up phase, with no differences reported
between the two treatment arms. Since the previous
analysis [7], only one new adverse event leading to
death has occurred in the treatment-free follow-up
phase: emphysema in the intravenous trastuzumab
arm. The overall cardiac safety profile of subcu-
taneous trastuzumab was consistent with intravenous
trastuzumab [21], and cardiac adverse events werecomparable between the treatment arms in the lower
body weight quartiles.
Along with the confirmation of efficacy and safety
data after a median follow-up of 40 months, which
support previous analyses [6,7], a notable outcome of
HannaH was the finding that in each of the two
treatment arms (there being almost 300 patients in
each arm), tpCR was associated with improved long-
term efficacy outcomes (EFS) in patients who
received neoadjuvanteadjuvant therapy for HER2-
positive early breast cancer, the risk of an EFS event
being reduced by >60%. The FDA has issued guidance
on the subject, concluding that favourable pCR results
are likely to predict clinical benefit [10,15]. The EMA
concludes that pCR may be acceptable as an end-point
for neoadjuvant early breast cancer trials under certain
conditions [16]. Present results are consistent with
other published studies in HER2-positive early breast
cancer[8,9,11e14] particularly NOAH [12], which
enrolled a more homogeneous population than the
other studies [8,9,11,13,14] and is most similar to
HannaH, albeit with a different concurrent neo-
adjuvant chemotherapy regimen. In NOAH, an
exploratory analysis also found a significant effect of
tpCR for EFS in the trastuzumab group [12]. It should
be noted that in HannaH the magnitude of EFS benefit
was comparable within the oestrogen receptor sub-
groups: achieving tpCR resulted in improved EFS
regardless of oestrogen receptor status. The Neo-
adjuvant Lapatinib and/or Trastuzumab Treatment
Optimisation (NeoALTTO) study showed a significant
improvement in pCR with neoadjuvant lapatinib plus
trastuzumab versus trastuzumab [11], while the Adju-
vant Lapatinib and/or Trastuzumab Treatment Opti-
misation (ALTTO) study reported no long-term
efficacy (disease-free survival) benefit in the adjuvant
setting [22]. However, it should be noted that the trial
designs and patient populations were different, and a
recent analysis of the two studies using the Collabo-
rative Trials in Neoadjuvant Breast Cancer
(CTNeoBC) methodology did not show discordance
C. Jackisch et al. / European Journal of Cancer 62 (2016) 62e75 73[23]. Indeed, applying the CTNeoBC methods
demonstrated that ALTTO’s results supported the
relationship between pCR and long-term efficacy [23]
Nevertheless, in HannaH, we demonstrate the
tpCReEFS relationship within the same patient pop-
ulation in the same study.
In light of the positive outcome in this HER2-
positive population, neoadjuvanteadjuvant systemic
treatment including at least trastuzumab every 3 weeks
for 18 cycles (1 year) should be offered to patients
regardless of their hormone receptor status. With this
option, long-term survival might subsequently be
increased. An additional option to improve tpCR
further for patients with HER2-positive early breast
cancer is the addition of pertuzumab to the neo-
adjuvant armamentarium, as was done in the Neo-
Sphere and ToleRabilitY of Pertuzumab, Herceptin
and AnthracyclinEs in NeoAdjuvant breast cancer
(TRYPHAENA) studies [24e26] which led to the
approval of neoadjuvant pertuzumab plus trastuzu-
mab plus docetaxel by the FDA and the EMA. Han-
naH’s results are consistent with recent NeoSphere
results, where patients who achieved tpCR with tras-
tuzumab plus docetaxel or trastuzumab plus pertuzu-
mab plus docetaxel had a reduced risk of both
progression-free and disease-free survival events [25].
HannaH’s large population, which includes almost 600
patients treated with trastuzumab randomised into
two separate study arms, adds further to the evidence
that tpCR is associated with favourable clinical
benefits.
Limitations of the present HannaH analysis include a
still relatively short median follow-up in view of the
long-term changes to the natural history of HER2-
positive breast cancer with the advent of targeted
treatments and improved prognosis over time. More-
over, the availability of newer anti-HER2 agents,
including pertuzumab and trastuzumab emtansine,
could impact survival in relapsing patients.
To conclude, in the present HannaH phase III
analysis with a median follow-up time of more than 40
months, the secondary long-term efficacy end-points,
EFS and OS, support the established non-inferiority of
subcutaneous trastuzumab relative to intravenous
trastuzumab as per the co-primary end-points, pCR
and Ctrough [6], and the safety profile of subcutaneous
trastuzumab continues to be consistent with the known
intravenous trastuzumab safety profile [21]. In each of
HannaH’s two treatment arms, comprising approxi-
mately 300 patients per arm, tpCR was associated with
improved long-term efficacy outcomes (EFS) in patients
who received neoadjuvanteadjuvant therapy for
HER2-positive early breast cancer. HannaH provides
the largest clinical dataset from a single study in HER2-
positive early breast cancer to demonstrate the
favourable association between tpCR and EFS to date,
and these data add to the body of evidence on tpCRbeing associated with clinical benefit in HER2-positive
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Research in context
Evidence before this study
Trastuzumab was originally given as a weight-based
intravenous dose until subcutaneous trastuzumab was
proven to be non-inferior in terms of serum trough con-
centration and pCR for the treatment of HER2-positive
early breast cancer [6]. Guidance from the Food and
Drug Administration (FDA) states that favourable
pCR (particularly tpCR) results are likely to predict
clinical benefit. To put the findings of the HannaH trial
into context with respect to associations between tpCR
and EFS (one of HannaH’s long-term secondary effi-
cacy end-points), we searched PubMed plus abstracts
from the American Society of Clinical Oncology annual
meetings, the San Antonio Breast Cancer Symposium
annual meetings, the European Society for Medical
Oncology biennial meetings, and the European Cancer
Congress biennial meetings with the terms ‘breast cancer’,
‘HER2’, ‘long term’, and ‘pathologic(al) complete
response’, selecting relevant English language publica-
tions within the last 5 years only. Studies indicated that
pCR/tpCR is likely to predict clinical benefit in patients
with HER2-positive early breast cancer [8e14].
Added value of this study
HannaH adds value to previous studies by virtue of its
being the largest trial of patients with HER2-positive
early breast cancer homogeneously treated with trastu-
zumab in the neoadjuvanteadjuvant setting to date:
almost 600 patients in total across two study arms. This
allowed us to add to the body of evidence comparing
patients by tpCR status and confirm the similarity of
subcutaneous and intravenous trastuzumab.
Implications of all the available evidence
In each of HannaH’s two treatment arms, comprising
approximately 300 patients per arm, tpCR was associated
with improved long-term efficacy outcomes (EFS) in pa-
tients who received neoadjuvanteadjuvant therapy for
HER2-positive early breast cancer. These data add to the
body of evidence on tpCR being associated with clinical
benefit in HER2-positive early breast cancer. HannaH also
confirmed no difference between subcutaneous and intra-
venous trastuzumab in terms of efficacy or safety with
longer follow-up.
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